Bone disease - metabolic
Methodology & AI Transparency ⓘ
Bone disease - metabolic Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code E88.9 in Weight & Metabolism, Bone disease - metabolic requires resting metabolic rate in Bone disease - metabolic (E88.9: context) so specialists can calibrate treatment intensity against DEXA Visceral Adipose in Bone disease - metabolic (E88.9: Tissue (VAT)) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Bone disease - metabolic uses ICD-10 E88.9 across Weight & Metabolism specialty care.
- 3 Typical cash cost range: Differential triage of Bone disease - metabolic (E88.9) utilizes resting metabolic rate in Bone disease - metabolic (E88.9: context).
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for Bone disease - metabolic (E88.9): DEXA Visceral Adipose in Bone disease - metabolic (E88.9: Tissue (VAT)) & Waist-to-Height Ratio [Bone disease - metabolic E88.9] (< 0.50 (E88.9)).
Ask our AI Specialists anything about Bone disease - metabolic
What Is Bone disease - metabolic?
Cataloged under federal diagnostic code E88.9 in Weight & Metabolism, Bone disease - metabolic requires resting metabolic rate in Bone disease - metabolic (E88.9: context) so specialists can calibrate treatment intensity against DEXA Visceral Adipose in Bone disease - metabolic (E88.9: Tissue (VAT)) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Bone disease - metabolic (E88.9) alters weight & metabolism homeostasis through adaptive thermogenic slowing [Bone disease - metabolic E88.9]; clinical remission targets Waist-to-Height Ratio [Bone disease - metabolic E88.9] within < 0.50 (E88.9).
Common Symptoms & Clinical Signs
- • Presentation of Bone disease - metabolic (E88.9): persistent hunger signaling [Bone disease - metabolic E88.9]
- • Secondary Bone disease - metabolic clinical sign: co-existing blood pressure, in Bone disease - metabolic (E88.9: triglyceride, or fasting)
- • Symptom flares in Bone disease - metabolic correlating with DEXA Visceral Adipose in Bone disease - metabolic (E88.9: Tissue (VAT)) deviation outside < 1.0 lb (< 100 cm2) (E88.9)
- • Functional weight & metabolism impact requiring resting metabolic rate in Bone disease - metabolic (E88.9: context) evaluation (E88.9)
Bone disease - metabolic Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Bone disease - metabolic (E88.9: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Bone disease - metabolic E88.9] | < 0.50 (E88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Bone disease - metabolic (E88.9: Index) | < 1.4 (E88.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bone disease - metabolic
Treatment selection for Bone disease - metabolic depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bone disease - metabolic)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone supplementation and bone: What a 3,103-Participant Study Found TRT is able to inhibit bone resorption and increase bone mass, particularly at the lumbar spine level and when the duration is long enough to allow the anabolic effect of T and estrogens on bone metabolism to take place. Journal of endocrinological investigation • 2022-05-15 • Meta-Analysis | N = 3,103 | 99/100 | PMID 35041193 ↗ |
| New Insights on Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone: What a 4,914-Participant Study Found High heterogeneity and diverse follow-up durations among studies were evident, which obscures the validity of the results. International journal of molecular sciences • 2024-07-22 • Meta-Analysis | N = 4,914 | 99/100 | PMID 39063229 ↗ |
| New Insights on Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia: What a 5,898-Participant Study Found A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898). JAMA psychiatry • 2026-09-01 • Meta-Analysis | N = 5,898 | 99/100 | PMID 42418179 ↗ |
| New Insights on Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc: What a 2,538-Participant Study Found Tirzepatide treatment was associated with sustained improvements in WHtR categories, with a greater proportion of participants shifting to a better WHtR category compared to participants treated with placebo. Journal of endocrinological investigation • 2026-06-15 • Phase III Randomized Trial | N = 2,538 | 96/100 | PMID 42082865 ↗ |
| New Insights on Contrasting Bone Profiles in PCOS Are Related to: What a 1,822-Participant Study Found The findings of this study alert for a low bone mass, low bone formation, and increased bone resorption PCOS with a BMI <27 kg/m2. The Journal of clinical endocrinology and metabolism • 2024-09-16 • Meta-Analysis | N = 1,822 | 94/100 | PMID 38739756 ↗ |
Bone disease - metabolic Patient Community & “People Like Me” Threads
Filter Bone disease - metabolic community threads and patient logs by age, biological sex, dosage, and treatment duration.